Previous close | 5.59 |
Open | 5.59 |
Bid | 4.90 |
Ask | 5.40 |
Strike | 105.00 |
Expiry date | 2024-11-15 |
Day's range | 5.59 - 5.59 |
Contract range | N/A |
Volume | |
Open interest | 76 |
DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
EDINBURGH, Scotland, June 20, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod® 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier1-3 diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,00